Sappok T, Faulstich A, Stuckert E, Kruck H, Marx P, Koennecke H C
Department of Neurology, Stroke Unit, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany.
Stroke. 2001 Aug;32(8):1884-9. doi: 10.1161/01.str.32.8.1884.
Compliance with pharmacological therapy is essential for the efficiency of secondary prevention of ischemic stroke. Few data exist regarding patient compliance with antithrombotic and risk factor treatment outside of controlled clinical trials. The aim of the present study was to assess the rate of and predictors for compliance with secondary stroke prevention 1 year after cerebral ischemia and to identify reasons for noncompliance.
Patients with a diagnosis of ischemic stroke or TIA and antithrombotic discharge medication were prospectively recruited. At 1 year, the proportion of patients compliant with antithrombotic treatment and with medication for risk factors (eg, hypertension, diabetes, hyperlipidemia) was evaluated through structured telephone interviews. In addition, the reasons for nontreatment with antithrombotic and risk factor medication were determined. Independent predictors for compliance were analyzed by logistic regression analyses.
Of 588 consecutive patients admitted to our stroke unit, 470 had a discharge diagnosis of cerebral ischemia (TIA 26.2%, cerebral infarct 73.8%) and recommendations for antithrombotic therapy. At 1 year, 63 patients (13.4%) had died and 21 (4.5%) were lost to follow-up, thus, 386 could finally be evaluated. Of the patients, 87.6% were still on antithrombotic medication, and 70.2% were treated with the same agent prescribed on discharge. Of the patients with hypertension, diabetes, and hyperlipidemia, 90.8%, 84.9%, and 70.2% were still treated for their respective risk factors. Logistic regression analyses revealed age (OR 1.03, 95% CI 1.00 to 1.06), stroke severity on admission (OR 1.09, 95% CI 1.00 to 1.20), and cardioembolic cause (OR 4.13, 95% CI 1.23 to 13.83) as independent predictors of compliance.
Compliance with secondary prevention in patients with ischemic stroke is rather good in the setting of our study. Higher age, a more severe neurological deficit on admission, and cardioembolic stroke cause are associated with better long-term compliance. Knowledge of these determinants may help to further improve the quality of stroke prevention.
药物治疗的依从性对于缺血性中风二级预防的效果至关重要。在对照临床试验之外,关于患者对抗血栓治疗和危险因素治疗的依从性的数据很少。本研究的目的是评估脑缺血后1年二级中风预防的依从率及预测因素,并确定不依从的原因。
前瞻性招募诊断为缺血性中风或短暂性脑缺血发作(TIA)且出院时带抗血栓药物的患者。在1年时,通过结构化电话访谈评估患者对抗血栓治疗及危险因素(如高血压、糖尿病、高脂血症)药物治疗的依从比例。此外,确定未进行抗血栓和危险因素药物治疗的原因。通过逻辑回归分析分析依从性的独立预测因素。
在连续入住我们卒中单元的588例患者中,470例出院诊断为脑缺血(TIA占26.2%,脑梗死占73.8%)并接受抗血栓治疗建议。1年时,63例(13.4%)患者死亡,21例(4.5%)失访,因此最终可评估386例患者。在这些患者中,87.6%仍在服用抗血栓药物,70.2%接受出院时开具的同一种药物治疗。在患有高血压、糖尿病和高脂血症的患者中,分别有90.8%、84.9%和70.2%仍在接受各自危险因素的治疗。逻辑回归分析显示年龄(比值比[OR]1.03,95%置信区间[CI]1.00至1.06)、入院时中风严重程度(OR 1.09,95%CI 1.00至1.20)和心源性栓塞病因(OR 4.13,95%CI 1.23至13.83)是依从性的独立预测因素。
在我们的研究背景下,缺血性中风患者二级预防的依从性相当好。年龄较大、入院时神经功能缺损较严重以及心源性栓塞性中风病因与更好的长期依从性相关。了解这些决定因素可能有助于进一步提高中风预防的质量。